PODD logo

Insulet Corporation Stock Price

NasdaqGS:PODD Community·US$21.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

PODD Share Price Performance

US$313.45
84.12 (36.68%)
13.0% undervalued intrinsic discount
US$360.17
Fair Value
US$313.45
84.12 (36.68%)
13.0% undervalued intrinsic discount
US$360.17
Fair Value
Price US$313.45
AnalystConsensusTarget US$360.17

PODD Community Narratives

AnalystConsensusTarget·
Fair Value US$360.17 13.0% undervalued intrinsic discount

Digital Diabetes Care Will Expand International Market Opportunities

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative

Recent PODD News & Updates

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher

Sep 06
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher

There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings

Aug 14
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings

Insulet Corporation Key Details

US$2.4b

Revenue

US$703.7m

Cost of Revenue

US$1.7b

Gross Profit

US$1.4b

Other Expenses

US$236.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
3.35
Gross Margin
70.18%
Net Profit Margin
10.01%
Debt/Equity Ratio
95.7%

Insulet Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

2 Risks
1 Reward

About PODD

Founded
2000
Employees
3900
CEO
Ashley McEvoy
WebsiteView website
www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.4%
  • 3 Months: 7.8%
  • 1 Year: 17.8%
  • Year to Date: 14.7%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 3.7% in that time. Meanwhile, the market is actually up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›